Immunologic biomarkers to predict efficacy of biological and systemic therapies for psoriasis

Psoriasis is one of the most common systemic chronic immune-mediated inflammatory diseases. Current treatment strategies for psoriasis focus on relieving symptoms, improving quality of life, and preventing disease progression. In the absence of a positive effect from the initial therapy, the issue of using various biological or low molecular weight drugs that affect certain immune mechanisms underlying the pathogenesis of the disease is considered. Current therapeutic strategies aim to develop new drugs that would block effector cytokine signaling. To date, there are no reliable predictors to predict which patient will respond positively to a particular type of systemic therapy. The search for biomarkers involved in the pathogenesis of the disease and/or reflecting the mechanism of action of drugs can help in answering these questions. The presented article will consider predictive immunological biomarkers of the effectiveness of psoriasis treatment with biological drugs (TNF-α inhibitors, IL-17 inhibitors, IL-23 inhibitors, type 4 phosphodiesterase inhibitors), which can be cytokines, chemokines, adipokines, soluble forms of cell surface receptors, markers of immune activation. In our paper, we do not consider new therapeutic strategies in psoriasis targeting small molecules that target JAK-STAT signaling pathways (Janus kinase inhibitors, tyrosine kinase 2 inhibitors, retinoid orphan nuclear receptor γt) preventing signaling downstream of IL-23 and IL-6. Given that many molecular cell mechanisms of the immune response are involved in the pathogenesis of psoriasis, it seems promising to search for combinations of these markers and draw up appropriate models for predicting an effective response to therapy based on them.

1. Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–212. https://doi.org/10.1111/jdv.13854.

2. Кубанов АА, Карамова АЭ, Притуло ОА, Аршинский МИ, Знаменская ЛФ, Чикин ВВ и др. Псориаз: клинические рекомендации. 2023. Режим доступа: https://cr.minzdrav.gov.ru/preview-cr/234_2.

3. Robinson WH, Lindstrom TM, Cheung RK, Sokolove J. Mechanistic biomarkers for clinical decision making in rheumatic diseases. Nat Rev Rheumatol. 2013;9(5):267–276. https://doi.org/10.1038/nrrheum.2013.14

4. Sanz-Martínez MT, Moga E, Sánchez Martínez MA, Zamora Atenza C, Vidal S, Juárez C et al. High Levels of Platelet-Lymphocyte Complexes in Patients with Psoriasis Are Associated with a Better Response to Anti-TNF-α Therapy. J Invest Dermatol. 2020;140(6):1176–1183. https://doi.org/10.1016/j.jid.2019.08.457.

5. Znamenskaya LF, Yegorovа YuYu, Zitner SV. Mechanism of the biological effect of the tumor necrosis factor-alpha at psoriasis. Vestnik Dermatologii i Venerologii. 2011;87(2):13–17. (In Russ.) https://doi.org/10.25208/vdv974.

6. Lu J, Tang S, Xie S, Yi X, Yu N, Gao Y et al. The potential of IL-12 in predicting clinical response to etanercept treatment in patients with psoriasis. Int J Clin Exp Med. 2016;9:23519–23524.

7. Kubanova АА, Proshutinskaya DV, Тekucheva LV, Avdiyenko IN. Integral approach to the external therapy of atopic dermatitis. Vestnik Dermatologii i Venerologii. 2010;86(1):57–66. (In Russ.) https://doi.org/10.25208/vdv801.

8. Karamova A, Znamenskaya L, Vorontsova A, Obraztsova O, Nikonorov A, Nikonorova E et al. Plasma cytokines for the prediction of the effectiveness of TNFα inhibitors etanercept, infliximab, and adalimumab in the treatment of psoriasis. J Clin Med. 2024;13(3):3895. https://doi.org/10.3390/jcm13133895.

9. Andersen CSB, Kvist-Hansen A, Siewertsen M, Enevold C, Hansen PR, KaurKnudsen D et al. Blood cell biomarkers of inflammation and cytokine levels as predictors of response to biologics in patients with psoriasis. Int J Mol Sci. 2023;24(7):6111. https://doi.org/10.3390/ijms24076111.

10. Borelli A, Irla M. Lymphotoxin: from the physiology to the regeneration of the thymic function. Cell Death Differ. 2021;28(8):2305–2314. https://doi.org/10.1038/s41418-021-00834-8.

11. Garashchenko NE, Seminskiy IZH. Lymphotoxin alpha: biological and clinical significance. Transbaikal Medical Bulletin. 2022;(1):44–55. (In Russ.) https://doi.org/10.52485/19986173_2022_1_44.

12. Conti F, Ceccarelli F, Marocchi E, Magrini L, Spinelli FR, Spadaro A et al. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis. 2007;66(10):1393–1397. https://doi.org/10.1136/ard.2007.073569.

13. Makos A, Kuiper JH, Kehoe O, Amarasena R. Psoriatic arthritis: review of potential biomarkers predicting response to TNF inhibitors. Inflammopharmacology. 2023;31(1):77–87. https://doi.org/10.1007/s10787-022-01092-x.

14. Chimenti MS, Perricone C, Graceffa D, Di Muzio G, Ballanti E, Guarino MD et al. Complement system in psoriatic arthritis: a useful marker in response prediction and monitoring of anti-TNF treatment. Clin Exp Rheumatol. 2012;30(1):23–30. Available at: https://pubmed.ncbi.nlm.nih.gov/22260811.

15. Scrivo R, Giardino AM, Salvarani C, Foti R, Afeltra A, Viapiana O et al. Predicting MDA in PsA Study Group. An observational prospective study on predictors of clinical response at six months in patients with active psoriatic arthritis treated with golimumab. Clin Exp Rheumatol. 2020;38(1): 107–114. Available at: https://www.ncbi.nlm.nih.gov/pubmed/31287400.

16. Andres-Ejarque R, Ale HB, Grys K, Tosi I, Solanky S, Ainali C et al. Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts nonresponse to adalimumab in psoriasis. Nat Commun. 2021;12(1):4741. https://doi.org/10.1038/s41467-021-25066-9.

17. Yu Y, Chen Z, Wang Y, Li Y, Lu J, Cui L et al. Infliximab modifies regulatory T cells and co-inhibitory receptor expression on circulating T cells in psoriasis. Int Immunopharmacol. 2021;96:107722. https://doi.org/10.1016/j.intimp.2021.107722.

18. Kwiek B, Narbutt J, SysaJędrzejowska A, Langner A, Lesiak A. Long-term treatment of chronic plaque psoriasis with biological drugs can control platelet activation: targeting the bridge between inflammation and atherothrombosis. Postepy Dermatol Alergol. 2017;34(2):131–137. https://doi.org/10.5114/ada.2017.67077.

19. Jiang Z, Jiang X, Chen A, He W. Platelet activation: a promoter for psoriasis and its comorbidity, cardiovascular disease. Front Immunol. 2023;14:1238647. https://doi.org/10.3389/fimmu.2023.1238647.

20. Tokuyama M, Mabuchi T. New treatment addressing the pathogenesis of psoriasis. Int J Mol Sci. 2020;21(20):7488. https://doi.org/10.3390/ijms21207488.

21. Ghoreschi K, Balato A, Enerbäck C, Sabat R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet. 2021;397(10275):754–766. https://doi.org/10.1016/S0140-6736(21)00184-7.

22. Aguilar-Flores C, Castro-Escamilla O, Ortega-Rocha EM, Maldonado- García C, Jurado-Santa Cruz F, Pérez-Montesinos G et al. Association of pathogenic Th17 cells with the disease severity and its potential implication for biological treatment selection in psoriasis patients. Mediators Inflamm. 2020;2020:8065147. https://doi.org/10.1155/2020/8065147.

23. Solberg SM, Aarebrot AK, Sarkar I, Petrovic A, Sandvik LF, Bergum B et al. Mass cytometry analysis of blood immune cells from psoriasis patients on biological therapy. Eur J Immunol. 2021;51(3):694–702. https://doi.org/10.1002/eji.202048857.

24. Ziolkowska-Banasik D, Hadas E, Pastuszczak M. Blood monocyte count can predict early response to secukinumab therapy in patients with psoriasis. J Drugs Dermatol. 2024;23(2):74–77. https://doi.org/10.36849/JDD.7525.

25. Morariu SH, Cotoi OS, Tiucă OM, Baican A, Gheucă-Solovăstru L, Decean H et al. Blood-count-derived inflammatory markers as predictors of response to biologics and small-molecule inhibitors in psoriasis: a multicenter study. J Clin Med. 2024;13(14):3992. https://doi.org/10.3390/jcm13143992.

26. Yang K, Oak ASW, Elewski BE. Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. Am J Clin Dermatol. 2021;22(2):173–192. https://doi.org/10.1007/s40257-020-00578-0.

27. Krueger JG, Eyerich K, Kuchroo VK, Ritchlin CT, Abreu MT, Elloso MM et al. IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy. Front Immunol. 2024;15:1331217. https://doi.org/10.3389/fimmu.2024.

28. Schett G, Chen W, Gao S, Chakravarty SD, Shawi M, Lavie F et al. Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study. Arthritis Res Ther. 2023;25(1):150. https://doi.org/10.1186/s13075-023-03125-4.

29. Siebert S, Coates LC, Schett G, Raychaudhuri SP, Chen W, Gao S et al. Modulation of Interleukin-23 signaling with guselkumab in biologic-naive patients versus tumor necrosis factor inhibitor-inadequate responders with active psoriatic arthritis. Arthritis Rheumatol. 2024;76(6):894–904. https://doi.org/10.1002/art.42803.

30. Marcelli L, Belcastro A, Talamonti M, Paganini C, Fico A, Savastano L et al. Characterization of super-responder profile in chronic plaque psoriatic patients under guselkumab treatment: a long-term real-life experience. J Clin Med. 2024;13(17):5175. https://doi.org/10.3390/jcm13175175.

31. Novikov PI, Moiseev ST. Efficacy and safety of apremilast in the treatment of psoriasis and psoriatic arthritis. Clinical Pharmacology and Therapy. 2018;27(4):66–70. (In Russ.) Available at: https://clinpharm-journal.ru/articles/2018-4/effektivnost-i-bezopasnost-apremilasta-v-lecheniipsoriaza-i-psoriaticheskogo-artrita.

32. Reid C, Griffiths CEM. Psoriasis and treatment: past, present and future aspects. Acta Derm Venereol. 2020;100(3):adv00032. https://doi.org/10.2340/00015555-3386.

33. Kubanov АА, Artamonova OG, Karamova АЕ, Vasileva EL, Deryabin DG. Cytokine Levels of Skin Lesions in Moderate and Severe Psoriasis as Predictors for the Type 4 Fosphodiesterase Inhibitor (Apremilast) Therapy Effectivness. Herald of the Russian Academy of Sciences. 2020;75(5):500–507. (In Russ.) https://doi.org/10.15690/vramn1361.

34. Artamonova OG, Karamova AE, Nikonorov AA, Verbenko DA, Vasileva EL, Kubanov АА. The effect of Janus kinase inhibitors and phosphodiesterase 4 inhibitors on skin and plasma cytokine levels in patients with psoriasis. Bulletin of Experimental Biology and Medicine. 2021;171(2):170–174. (In Russ.) https://doi.org/10.47056/0365-9615-2021-171-2-170-174.